N2A CELL LINE AND NEURONAL PRIMARY CULTURES AS PLATFORMS TO EVALUATE NEUROPROTECTIVE AND NEUROPLASTIC ACTIVITIES OF HUMAN ERYTHROPOIETIN

RICARDO KRATJE; MARÍA DE LOS MILAGROS BÜRGI; CAMILA SCORTICATI; GABRIELA INÉS APARICIO; MARCOS OGGERO

Río de Janeiro

Simposio; 8º Simposio Latino-Americano de tecnología de cultivos celulares; 2019

8th SLATCC Comitee

Neurodegenerative diseases are pathologies that affect the nervous system and cause cognitive disorders, behavior disorders and physiological changes. They are characterized by their chronicity and progressive evolution. According to the World Health Organization (WHO), neurodegenerative diseases affect millions of people around the world, mainly due to the increase in life expectancy and the concomitant increase in the world's elderly population. Nowadays, there is not treatment with perceptible advantages for these pathologies. Because of that, researchers are involved in the development of neuroprotective and/or neurotropic agents. In this aspect, hEPO (human erythropoietin) has an important role considering its antiapoptotic, cytoprotective, angiogenic and antioxidant properties.In this work, the in vitro neuroprotective and neuroplastic activity of rhEPO (recombinant human erythropoietin) were determined employing murine neuroblastoma cell line (N2a) and primary cultures from hippocampal neurons. In both cases, the capacity of the cytokine to reverse the staurosporine (STP)-induced apoptosis was studied. Different conditions were assayed, demonstrating the cytoprotective role of rhEPO to protect STP-treated N2a cell lines and primary cultures at 5 and 11 DIV (days in vitro). rhEPO was capable to significantly reverse the STP-induced apoptosis in a dose-response effect in both cells types (between p